NCT03136835View on ClinicalTrials.gov

Maternal Hyperoxygenation in Congenital Heart Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

March 22, 2024

Study Completion Date

March 22, 2024

Conditions
Hypoplastic Left Heart Syndrome
Interventions
DRUG

Maternal Hyperoxygenation

Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth

Trial Locations (1)

M5G 1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT03136835 - Maternal Hyperoxygenation in Congenital Heart Disease | Biotech Hunter | Biotech Hunter